Research Topics
Genomes and Genes | Wyndham H WilsonSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtypeWyndham H Wilson
Metabolism Branch, National Cancer Institute, Bethesda, MD 20892, USA
Haematologica 97:758-65. 2012..The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting...
Novel disease targets and management approaches for diffuse large B-cell lymphomaWyndham H Wilson
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Leuk Lymphoma 51:1-10. 2010..As more targeted agents are developed, the timing of administration with other agents in clinical trials will become increasingly important to ensure maximal efficacy while minimizing side effects...- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H Wilson
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Lancet Oncol 11:1149-59. 2010..We aimed to assess the safety and antitumour activity of navitoclax in patients with lymphoid tumours, and establish the drug's pharmacokinetic and pharmacodynamic profiles... - Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson
Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 26:2717-24. 2008.... - Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 30:830-6. 2012..To this end, we developed a novel regimen by adding fludarabine to dose-adjusted continuous-infusion etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus with or without rituximab (DA-EPOCH-F/R)... - The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphomaKieron Dunleavy
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Blood 115:3017-24. 2010..However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death. This trial was registered at www.clinicaltrials.gov as NCT000019253... - Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Blood 113:6069-76. 2009..This trial is registered with http://www.ClinicalTrials.gov under identifier NCT00057902... - Rituximab-associated neutropeniaKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Semin Hematol 47:180-6. 2010..Late-onset neutropenia is intriguing biologically and while its pathogenesis and mechanism are not completely understood, many interesting hypotheses have been proposed to explain its occurrence... 
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyRichard F Little
Center for Cancer Research (CCR, National Cancer Institute (NCI, National Institutes of Health, Bethesda, MD 20892, USA
Blood 101:4653-9. 2003..These results suggest that tumor pathogenesis is responsible for the improved outcome of ARLs in the era of HAART...- Molecular diagnosis of Burkitt's lymphomaSandeep S Dave
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
N Engl J Med 354:2431-42. 2006..CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma... - Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cellsSandeep S Dave
National Cancer Institute, NIH, Bethesda, MD 20892, USA
N Engl J Med 351:2159-69. 2004..CONCLUSIONS: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis... - Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphomaJohn E Janik
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 104:3355-7. 2004..Serum sIL-2R levels were elevated in both patients with recurrent disease... - Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaAndreas Rosenwald
Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
J Exp Med 198:851-62. 2003..The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL... - Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Blood 99:2685-93. 2002..Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens. Dynamic dose adjustment may overcome inadequate drug concentrations, particularly in younger patients, and compensate for increased drug clearance over time... - Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19James N Kochenderfer
Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
Blood 116:4099-102. 2010..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326... - Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?Kieron Dunleavy
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Rockville Pk, Bethesda, MD 20892, USA
Curr Hematol Malig Rep 7:241-7. 2012.... - Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphomaMarc A Weniger
Hematology Branch, NHLBI, NIH, Building 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 MD, USA
Clin Cancer Res 17:5101-12. 2011..Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasome inhibition, cellular response, and clinical efficacy... - The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaAndreas Rosenwald
The Lymphoma/Leukemia Molecular Profiling Project, National Cancer Institute/NIH, Bethesda, MD, USA
Cancer Cell 3:185-97. 2003..We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy... - Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlationHeba A Degheidy
Division of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
Cytometry B Clin Cytom 80:309-17. 2011..In a companion methodological study, we compared two anti-ZAP-70 clones (1E7.2 AF 488 and SBZAP PE) and four selected methods of analysis. Clinical correlations are required for validation... - Methodological comparison of two anti-ZAP-70 antibodiesHeba A Degheidy
Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
Cytometry B Clin Cytom 80:300-8. 2011..ZAP-70 expression is a stage independent prognostic marker in CLL. However, interlaboratory variation is large, and there is neither a consensus nor a regulatory approved methodology... - Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphomaSattva S Neelapu
Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
Nat Med 11:986-91. 2005..Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses... - Targeting malignant B cells with an immunotoxin against ROR1Sivasubramanian Baskar
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
MAbs 4:349-61. 2012..Our data suggest that ROR1-immunotoxins such as BT-1 could serve as targeted therapeutic agents for ROR1-expressing B cell malignancies and other cancers... - The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-RWyndham H Wilson
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Semin Oncol 29:41-7. 2002..These results suggest that rituximab may modulate the sensitivity of B-cell lymphomas to chemotherapy... - High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytologyUpendra Hegde
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD 20892-1868, USA
Blood 105:496-502. 2005..Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry... - Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphomaFranziska C Eberle
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Am J Surg Pathol 36:716-25. 2012..We show that cHL is less often associated with MF and primary cutaneous CD30-T-LPD than previously thought and that the coexpression of CD30 and CD15 in these TCLs may lead to a mistaken diagnosis of cHL... - B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsJames N Kochenderfer
Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
Blood 119:2709-20. 2012.... - The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaYair Herishanu
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 117:563-74. 2011..These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370... - Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphomaRobert M Dean
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1203, USA
Biol Blood Marrow Transplant 11:593-9. 2005.... - Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaRobert J Kreitman
Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
J Clin Oncol 27:2983-90. 2009..To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL... - Focus on lymphomasLouis M Staudt
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Cancer Cell 2:363-6. 2002 - Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlationsFranziska C Eberle
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Mod Pathol 24:1586-97. 2011.... - B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasisKieron Dunleavy
Experimental Transplantation and Immunology Branch, CCR, NCI, Bldg 10, Rm 12 N 226, Bethesda, MD, 20892 1868, USA
Blood 106:795-802. 2005..These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis... - Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphomaJoo Y Song
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Am J Surg Pathol 35:767-72. 2011..NLPHL and cHL are 2 distinct diseases and are almost never seen concurrently. We present a case in which polymerase chain reaction analysis indicated that the tumor cells of these 2 distinct entities were clonally identical... - Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationPatricia Perez-Galan
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 117:542-52. 2011..Expression of CD38 and IRF4 could serve as markers of bortezomib resistance in MCL. This study has been registered at http://clinicaltrials.gov as NCT00131976... - Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression responseAndreas Rosenwald
Metabolism Branch, Center for Cancer Research, National Cancer Institute/NIH, Bldg 10, Rm 4N114, Bethesda, MD 20892, USA
Blood 104:1428-34. 2004..These considerations suggest that fludarabine treatment should be given in strict accordance to the current National Cancer Institute (NCI) guidelines that have established criteria of disease activity that warrant treatment... - Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemiaGerald E Marti
Laboratory of Stem Cell Biology, Cellular and Tissue Therapy Branch, Division of Cell and Gene Therapies, Office of Cellular, Tissues and Gene Therapies, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Leuk Lymphoma 52:2284-92. 2011..UCN-01 does not increase FAMP toxicity. Transient lymphocytosis followed by apoptosis occurs with UCN-01. Mobilization from tissue reservoirs may play a role in the induction of cell death in malignant lymphocytes... - Circulating serum free light chains as predictive markers of AIDS-related lymphomaOla Landgren
National Cancer Institute, National Institutes of Health, Center for Cancer Research, Medical Oncology Branch, 9000 Rockville Pike, Bldg 10 Room 13N240, Bethesda, MD, 20892, USA
J Clin Oncol 28:773-9. 2010..CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk... - Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?Cliona Grant
Metabolism Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
Curr Hematol Malig Rep 6:157-63. 2011..Historical data indicate that they have done poorly with traditional approaches developed for the treatment of either CHL or diffuse large B-cell lymphoma... - EBV-associated lymphomas in adultsMark Roschewski
Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
Best Pract Res Clin Haematol 25:75-89. 2012.... - Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processesKieron Dunleavy
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Curr Hematol Malig Rep 7:208-15. 2012.... - New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1868, USA
Clin Cancer Res 16:5608-17. 2010..In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL... - High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patientsBrad Moriyama
National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD 20892, USA
Ann Pharmacother 44:929-35. 2010..To report a case series of high-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections... - Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemiaRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Leuk Lymphoma 52:82-6. 2011..In separate randomized trials, rituximab is undergoing phase II testing with cladribine for early HCL and with bendamustine or pentostatin for multiply relapsed HCL... - Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomasMichael R Bishop
Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Biol Blood Marrow Transplant 9:162-9. 2003.... - A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancyJohn C Morris
Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
Clin Cancer Res 13:958-64. 2007..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points... - The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphomaKieron Dunleavy
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Leuk Lymphoma 48:1061-3. 2007 - How I treat HIV-associated lymphomaKieron Dunleavy
Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
Blood 119:3245-55. 2012..Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy... - Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survivalAdrian Wiestner
Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
Blood 109:4599-606. 2007..We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients... - Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapyWendy B Bernstein
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1868, USA
Int J Hematol 84:3-11. 2006..Strategies for prevention, screening, and therapy remain important areas of research in this developing field... - Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptorJames N Kochenderfer
Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother 32:689-702. 2009.... - Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progressionHaipeng Shao
Laboratory of Pathology and the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Am J Surg Pathol 34:1425-35. 2010..Our results suggest that IgA plasmacytomas may represent a distinct form of extramedullary plasmacytoma characterized by younger age at presentation, frequent lymph node involvement, and low risk of progression to plasma cell myeloma... - Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 23:6719-29. 2005..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin... - Novel agents for B-cell non-Hodgkin lymphoma: science and the promiseKevin Tay
Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Centre Drive, Bethesda, MD 20892 1203, USA
Blood Rev 24:69-82. 2010..The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in non-Hodgkin lymphoma... - A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell LymphomaKieron Dunleavy
National Cancer Institute, Bethesda, MD
Clin Lymphoma Myeloma Leuk 10:E27. 2010..TLS occurred infrequently and was reversible. DLTs were TLS and gastrointestinal toxicity. Accrual continues. Analysis of cell cycle and transcriptional CDK targets is ongoing... - Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaRobert J Kreitman
National Cancer Institute, National Institutesof Health, Bethesda, USA
J Clin Oncol 30:1822-8. 2012..To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL)... - Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemiaSivasubramanian Baskar
Experimental Transplantation and Immunology Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1203, USA
Clin Cancer Res 14:396-404. 2008..To assess the suitability of ROR1 as a cell surface antigen for targeted therapy of B-CLL, we carried out a comprehensive analysis of ROR1 protein expression... - Primary intraocular lymphoma: current and future perspectivesKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD, USA
Leuk Lymphoma 47:1726-7. 2006 - Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemiaUpendra P Hegde
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Blood 100:2260-2. 2002..These results suggest rituximab can rapidly reverse refractory fludarabine-associated ITP... - ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Blood 101:4944-51. 2003..We developed reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP-70 expression that can be applied clinically and would yield important prognostic information for patients with CLL... - Lymphomatoid granulomatosis: abnormalities of the brain at MR imagingAthos D Patsalides
Department of Diagnostic Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bldg 10, Room 1C660, 9000 Rockville Pike, Bethesda, MD 20892 1182, USA
Radiology 237:265-73. 2005..To retrospectively evaluate the magnetic resonance (MR) imaging features of lymphomatoid granulomatosis in the brain... - Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaR Eric Davis
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nature 463:88-92. 2010..These findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies... - Combined normal donor and CLL: Single tube ZAP-70 analysisHeba A Degheidy
Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA
Cytometry B Clin Cytom 82:67-77. 2012..Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment... - The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphomaAndreas Rosenwald
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
N Engl J Med 346:1937-47. 2002..CONCLUSIONS: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma... - The pharmacokinetics of rituximab following an intravitreal injectionHyuncheol Kim
National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1863, USA
Exp Eye Res 82:760-6. 2006.... - Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implicationsKieron Dunleavy
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Curr Opin Hematol 14:348-53. 2007..The prognosis with traditional chemotherapy has been poor, but improved understanding of the disease's pathobiology has led to several promising novel therapeutic strategies... - Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphomaFranziska C Eberle
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Haematologica 96:558-66. 2011..Epigenetic changes have been implicated in the loss of the B-cell program in classical Hodgkin's lymphoma, and might provide a basis for the immunophenotypic alterations seen in mediastinal gray zone lymphoma... - A novel role for IL-22R1 as a driver of inflammationRam Savan
Cancer and Inflammation Program, Center for Cancer Research, Frederick, MD, USA
Blood 117:575-84. 2011..This study documents a previously unknown role of IL-22R1 in inflammation and identifies the involvement of IL-22R1/IL-22 in ALK(+)ALCL... - Mycosis fungoides and Sézary syndromeSam T Hwang
Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
Lancet 371:945-57. 2008.... - International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the futureRobert B Nussenblatt
Laboratory of Immunology, National Eye Institute, NIH, 10 Center Drive, Building 10, Room 10S219, Bethesda, MD, 20892, USA
Ocul Immunol Inflamm 14:139-44. 2006..To bring together multidisciplinary experts to discuss primary central nervous system lymphoma (PCNSL) and primary intraocular lymphoma (PIOL)... - Drug resistance in diffuse large B-cell lymphomaWyndham H Wilson
Center for Cancer Treatment, National Cancer Institute, Bethesda, MD
Semin Hematol 43:230-9. 2006..However, the complexity of drug resistance requires that future clinical trials incorporate molecular translational endpoints to help identify the biologic basis of treatment failure... - Cardiac involvement with lymphoma: a review of the literatureDeirdre O'Mahony
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Clin Lymphoma Myeloma 8:249-52. 2008..We present 2 cases and a review of the literature... - Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemiaGeorg Aue
Hematology Branch, National Heart, Lung, and Blood Institute NIH, 10 Center Drive, Bethesda, MD 20892 1202, USA
Haematologica 94:1266-73. 2009..We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia... - Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature reviewGregory D Leonard
National Cancer Institute, Bethesda, Maryland 20892, USA
Leuk Lymphoma 45:2521-5. 2004..With appropriate chemotherapy and hematological support, lymphoma associated with Job's syndrome can achieve complete remission... - Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphomaW Tait Stevens
Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland 20892, USA
Transfusion 44:1679. 2004 - The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphomaKieron Dunleavy
National Cancer Institute, Bethesda, MD 20892, USA
Leuk Lymphoma 51:28-33. 2010..Current limitations of the technique will be summarized, and innovative uses of PET in grading, staging, and surveying lymphomas will be briefly explored... - Radiofrequency ablation of lymphomaDeepak Sudheendra
Department of Radiology, National Institutes of Health, Bldg 10, Rm 1C-660, Bethesda, MD 20892, USA
Blood 107:1624-6. 2006..RF ablation may be clinically beneficial and should be considered for the treatment of local lymphoma that is refractory or not amenable to standard approaches... - Extraoular muscle palsies in subcutaneous panniculitis-like T-cell lymphomaGregory D Leonard
Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 21:2993-5. 2003 - Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategyKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Leuk Lymphoma 48:449-51. 2007